ERBB2 and glioblastoma: In addition to HER2, expression levels of other antigens in GBM impair the function of HER2-CAR-T because the diversity of GBM cell antigens makes it impossible to identify HER2 antigens, thereby affecting the efficiency of tumor treatment.